{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:34:02Z","timestamp":1786707242962,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.tranon.2023.101718","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T20:37:10Z","timestamp":1687639030000},"page":"101718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Hiroki","family":"Osumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Yoshinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izuma","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2023.101718_bib0001","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1002\/cncr.28143","article-title":"Changing prognosis of metastatic colorectal adenocarcinoma: differential improvement by age and tumor location","volume":"119","author":"Golan","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2023.101718_bib0002","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jval.2019.07.009","article-title":"Cost-effectiveness of RAS genetic testing strategies in patients with metastatic colorectal cancer: a systematic review","volume":"23","author":"Unim","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.tranon.2023.101718_bib0003","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.tranon.2023.101718_bib0004","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0005","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.tranon.2023.101718_bib0006","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.tranon.2023.101718_bib0007","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0008","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0011","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2023.101718_bib0012","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0013","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0014","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2023.101718_bib0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0016","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0017","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2019.37.4_suppl.585","article-title":"Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: additional study of E-rechallenge trial","volume":"37","author":"Ohhara","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0018","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1200\/PO.20.00109","article-title":"RAS mutations in circulating tumor DNA and clinical outcomes of rechallenge treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer","volume":"4","author":"Sunakawa","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00277","article-title":"EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment","volume":"2","author":"Gazzaniga","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0020","article-title":"Undetectable RAS-mutant clones in plasma: possible implication for anti-EGFR therapy and prognosis in patients with RAS-mutant metastatic colorectal cancer","volume":"4","author":"Bouchahda","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0021","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3389\/fonc.2020.01115","article-title":"Evolution of RAS mutational status in liquid biopsies during first-line chemotherapy for metastatic colorectal cancer","volume":"10","author":"Klein-Scory","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0022","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/cancers11010042","article-title":"Transient disappearance of RAS mutant clones in plasma: a counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer","volume":"11","author":"Raimondi","year":"2019","journal-title":"Cancer. (Basel)"},{"key":"10.1016\/j.tranon.2023.101718_bib0023","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/ijc.32657","article-title":"Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer","volume":"147","author":"Moati","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2023.101718_bib0024","doi-asserted-by":"crossref","first-page":"viii181","DOI":"10.1093\/annonc\/mdy281.089","article-title":"Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation","volume":"29","author":"Sunakawa","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0025","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.3390\/cancers12123633","article-title":"Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients","volume":"12","author":"Nicolazzo","year":"2020","journal-title":"Cancer. (Basel)"},{"key":"10.1016\/j.tranon.2023.101718_bib0026","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.21873\/anticanres.15740","article-title":"Chemotherapy-induced reversion of mutant RAS to wild-type RAS in metastatic colorectal cancer","volume":"42","author":"Sato","year":"2022","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2023.101718_bib0027","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2021.05.010","article-title":"NeoRAS wild-type in metastatic colorectal cancer: myth or truth?-Case series and review of the literature","volume":"153","author":"Osumi","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2023.101718_bib0028","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.neo.2018.10.004","article-title":"Clinical validation of newly developed multiplex kit using luminex xMAP technology for detecting simultaneous RAS and BRAF mutations in colorectal cancer: results of the RASKET-B study","volume":"20","author":"Taniguchi","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.tranon.2023.101718_bib0029","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41416-019-0457-y","article-title":"A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer","volume":"120","author":"Bando","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2023.101718_bib0030","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/s12885-021-08395-2","article-title":"REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer","volume":"21","author":"Nakajima","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2023.101718_bib0031","doi-asserted-by":"crossref","first-page":"175","DOI":"10.23922\/jarc.2019-018","article-title":"Japanese classification of colorectal, appendiceal, and anal carcinoma: the 3d English edition [secondary publication]","volume":"3","year":"2019","journal-title":"J. Anus. Rectum. Colon"},{"key":"10.1016\/j.tranon.2023.101718_bib0032","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.tranon.2023.101718_bib0033","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/cas.13972","article-title":"Clinical utility of circulating tumor DNA for colorectal cancer","volume":"110","author":"Osumi","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2023.101718_bib0034","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.2020.38.4_suppl.180","article-title":"NeoRAS: incidence of RAS reversion from RAS mutated to RAS wild type","volume":"38","author":"Henry","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0035","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2023.101718_bib0036","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0037","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2023.101718_bib0038","doi-asserted-by":"crossref","first-page":"iv23","DOI":"10.1093\/annonc\/mdz155.088","article-title":"FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX\/CAPOX plus bevacizumab-based treatment: phase II CONVERTIX trial","volume":"30","author":"Fern\u00e1ndez Montes","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2023.101718_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063071","article-title":"Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol","volume":"12","author":"Osumi","year":"2022","journal-title":"BMJ Open"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523323001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523323001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:26:08Z","timestamp":1761845168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523323001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":39,"alternative-id":["S1936523323001043"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2023.101718","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2023.101718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101718"}}